首页> 美国卫生研究院文献>Materials >Photoactive Pore Matrix for In Situ Delivery of a Photosensitizer in Vascular Smooth Muscle Cells Selective PDT
【2h】

Photoactive Pore Matrix for In Situ Delivery of a Photosensitizer in Vascular Smooth Muscle Cells Selective PDT

机译:光敏孔基质用于在血管平滑肌细胞选择性PDT中原位递送光敏剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study we present the porous silica-based material that can be used for in situ drug delivery, offering effective supply of active compounds regardless its water solubility. To demonstrate usability of this new material, three silica-based materials with different pore size distribution as a matrix for doping with Photolon (Ph) and Protoporphyrin IX (PPIX) photosensitizers, were prepared. These matrices can be used for coating cardiovascular stents used for treatment of the coronary artery disease and enable intravascular photodynamic therapy (PDT), which can modulate the vascular response to injury caused by stent implantation—procedure that should be thought as an alternative for drug eluting stent. The FTIR spectroscopic analysis confirmed that all studied matrices have been successfully functionalized with the target photosensitizers. Atomic force microscopy revealed that resulting photoactive matrices were very smooth, which can limit the implantation damage and reduce the risk of restenosis. No viability loss of human peripheral blood lymphocytes and no erythrocyte hemolysis upon prolonged incubations on matrices indicated good biocompatibility of designed materials. The suitability of photoactive surfaces for PDT was tested in two cell lines relevant to stent implantation: vascular endothelial cells (HUVECs) and vascular smooth muscle cells (VSMC). It was demonstrated that 2 h incubation on the silica matrices was sufficient for uptake of the encapsulated photosensitizers. Moreover, the amount of the absorbed photosensitizer was sufficient for induction of a phototoxic reaction as shown by a rise of the reactive oxygen species in photosensitized VSMC. On the other hand, limited reactive oxygen species (ROS) induction in HUVECs in our experimental set up suggests that the proposed method of PDT may be less harmful for the endothelial cells and may decrease a risk of the restenosis. Presented data clearly demonstrate that porous silica-based matrices are capable of in situ delivery of photosensitizer for PDT of VSMC.
机译:在这项研究中,我们介绍了可用于原位药物递送的多孔二氧化硅基材料,无论其水溶性如何,均可提供有效的活性化合物供应。为了证明这种新材料的可用性,制备了三种具有不同孔径分布的二氧化硅基材料,作为掺杂光子(Ph)和原卟啉IX(PPIX)光敏剂的基质。这些基质可用于涂覆用于治疗冠状动脉疾病的心血管支架,并能够进行血管内光动力疗法(PDT),该疗法可调节血管对支架植入引起的损伤的反应-该过程应被视为药物洗脱的替代方法支架。 FTIR光谱分析证实,所有研究的基质均已成功地用目标光敏剂功能化。原子力显微镜显示,所得的光敏基质非常光滑,可以限制植入物的损害并降低发生再狭窄的风险。在基质上长时间温育后,人外周血淋巴细胞没有活力丧失,并且没有红细胞溶血表明所设计材料具有良好的生物相容性。在与支架植入相关的两种细胞系中测试了光敏表面对PDT的适用性:血管内皮细胞(HUVEC)和血管平滑肌细胞(VSMC)。已经证明,在二氧化硅基质上温育2小时足以摄取封装的光敏剂。此外,吸收的光敏剂的量足以引起光毒性反应,如光敏的VSMC中活性氧种类的增加所表明的。另一方面,在我们的实验装置中,HUVEC中有限的活性氧(ROS)诱导表明,所提出的PDT方法对内皮细胞的危害较小,并且可以降低发生再狭窄的风险。呈现的数据清楚地表明,基于多孔二氧化硅的基质能够原位递送用于VSMC PDT的光敏剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号